Katsuyuki Hotta

  • 5748 Citations
  • 29 h-Index
19982019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Katsuyuki Hotta is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 30 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Survival Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 5748 Citations
  • 29 h-Index
  • 208 Article
  • 3 Review article
  • 1 Comment/debate
  • 1 Letter

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

Harada, D., Kozuki, T., Nogami, N., Bessho, A., Hosokawa, S., Fukamatsu, N., Hotta, K., Oohashi, K., Kubo, T., Yoshioka, H., Yokoyama, T., Sone, N., Kuyama, S., Kudo, K., Yasugi, M., Takigawa, N., Oze, I. & Kiura, K., Jan 1 2019, In : Asia-Pacific Journal of Clinical Oncology.

Research output: Contribution to journalArticle

Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Nanoparticles
Appointments and Schedules

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cacers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

Ninomiya, K., Hata, T., Yoshioka, H., Oohashi, K., Bessho, A., Hosokawa, S., Ishikawa, N., Yamasaki, M., Shibayama, T., Aoe, K., Kozuki, T., Harita, S., Ueda, Y., Murakami, T., Fujimoto, N., Yanai, H., Toyooka, S., Takata, M., Hotta, K., Kiura, K. & 108 others, Gemba, K., Ikeda, G., Yasugi, M., Kurimoto, E., Nakano, K., Moritaka, T., Inoue, K., Miyoshi, S., Hamaguchi, N., Ito, R., Sano, Y., Takata, I., Mitani, A., Nishisaka, T., Shoda, H., Nishida, A., Tamamoto, S., Fujitaka, K., Masuda, T., Miyamoto, S., Hattori, N., Sugimoto, K., Fujii, S., Ueda, Y., Sakugawa, Y., Fukamatsu, N., Ogata, K., Bandoh, S., Kanaji, N., Takigawa, N., Yamane, H., Ochi, N., Honda, Y., Oka, M., Kittaka, M., Kubota, T., Yokoyama, A., Yokoyama, T., Sato, E., Shiota, Y., Horita, N., Kanematsu, T., Awaya, Y., Nakamasu, A., Murakami, I., Kuyama, S., Kudo, K., Tamura, T., Umeno, T., Morichika, D., Fujiwara, K., Sato, K., Harada, D., Nogami, N., Nishii, K., Fuchimoto, Y., Kishimoto, T., Kawai, H., Watanabe, K., Tokumo, K., Isobe, T., Tsubata, Y., Inoue, M., Ichikawa, H., Nishioka, Y., Hanibuchi, M., Goto, H., Sumikawa, T., Kodani, M., Suyama, H., Makino, H., Kinosita, N., Shimizu, E., Obata, H., Ikegami, H., Chikamori, K., Maeda, T., Kishino, T., Kamei, H., Ueoka, H., Kunihiro, Y., Kobayashi, T., Ueda, K., Hayashi, M., Kamiya, M., Murakami, J., Sato, A., Ichihara, E., Kubo, T., Ninomiya, T., Hirata, T., Minami, D., Kato, Y., Higo, H., Makimoto, G., Toyota, Y., Oda, N., Nakanishi, M., Kayatani, H., Senoo, S., Kano, H., Watanabe, H., Ando, T., Nakasuka, T., Hara, N., Itano, J., Nakashima, H. & Tabata, M., Jan 1 2019, In : Chest.

Research output: Contribution to journalArticle

Epidermal Growth Factor
Japan
Cohort Studies
Prospective Studies
Lung
1 Citation (Scopus)
Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
osimertinib
Prospective Studies

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Higo, H., Kubo, T., Makimoto, S., Makimoto, G., Ihara, H., Masaoka, Y., Ninomiya, T., Ichihara, E., Oohashi, K., Sato, A., Hotta, K., Tabata, M., Takigawa, N., Maeda, Y. & Kiura, K., Jan 1 2019, In : Japanese journal of clinical oncology. 49, 5, p. 458-464 7 p.

Research output: Contribution to journalArticle

Chemoradiotherapy
Lung Neoplasms
Lung
Radiation Pneumonitis
Tomography

Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62](S0169500219300212)(10.1016/j.lungcan.2019.01.005)

Watanabe, S., Yoshioka, H., Sakai, H., Hotta, K., Takenoyama, M., Yamada, K., Sugawara, S., Takiguchi, Y., Hosomi, Y., Tomii, K., Niho, S., Yamamoto, N., Nishio, M., Ohe, Y., Kato, T., Takahashi, T., Kamada, A., Suzukawa, K., Omori, Y., Enatsu, S. & 2 others, Nakagawa, K. & Tamura, T., Jan 1 2019, In : Lung Cancer.

Research output: Contribution to journalComment/debate

Open Access
gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Lung Neoplasms
Japan